Ethyl 6,7-difluoro-1-methyl-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate

We are Ethyl 6,7-difluoro-1-methyl-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate CAS:113046-72-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  Ethyl 6,7-difluoro-1-methyl-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate
CAS.NO:  113046-72-3
Synonyms:
6,7-Difluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic Acid Ethyl Ester

Molecular Formula: C14H11F2NO3S
Molecular Weight:   311.30400

Physical and Chemical Properties:
Density: 1.5g / cm3
Boiling point: 436.8ºC at 760mmHg
Flash point: 218ºC
Refractive index: 1.625

Specification:
Appearance: Light yellow to yellow crystalline powder
Purity:≥98.0%
Fluorin:3.5-5.0% 
Acetonitrile:≤0.4%
Loss on drying:≤1.0%
Residue on ignition:≤0.1%
Heavy metal:≤20ppm
Residue solvents:Should be complies
Total impurity:≤1.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
An ester of a fluorinated [1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid derivative with bactericidal activity. Intermediates of Prulifloxacin CAS:123447-63-2.

Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.34272-64-5 In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.4-Amino-3-bromo-2-chloropyridine CAS:215364-85-5 Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.D-homofenilalanina CAS:82795-51-5 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.